TransMedics Group, Inc. (TMDX) Shareholder Equity
- 2026-06-30: Common Stock, Value, IssuedUSD $774.22M; Accumulated Other Comprehensive Income (Loss), Net of TaxUSD $-210.00K; Retained Earnings (Accumulated Deficit)USD $-255.95M; Stockholders' Equity Attributable to ParentUSD $518.05M.
- 2026-03-31: Common Stock, Value, IssuedUSD $764.64M; Accumulated Other Comprehensive Income (Loss), Net of TaxUSD $2.00K; Retained Earnings (Accumulated Deficit)USD $-270.63M; Stockholders' Equity Attributable to ParentUSD $494.01M.
- 2025-12-31: Common Stock, Value, IssuedUSD $750.93M; Accumulated Other Comprehensive Income (Loss), Net of TaxUSD $124.00K; Retained Earnings (Accumulated Deficit)USD $-277.95M; Stockholders' Equity Attributable to ParentUSD $473.10M.
- 2025-09-30: Common Stock, Value, IssuedUSD $738.43M; Accumulated Other Comprehensive Income (Loss), Net of TaxUSD $101.00K; Retained Earnings (Accumulated Deficit)USD $-383.33M; Stockholders' Equity Attributable to ParentUSD $355.20M.
TransMedics Group, Inc. Shareholder Equity
Filed components and totals, with each concept and unit kept separate. Components can overlap; they are not added together. Missing disclosures remain (m). Original concept pages retain their detailed breakdowns and history.
| Period end | Common Stock, Value, Issued USD | Accumulated Other Comprehensive Income (Loss), Net of Tax USD | Retained Earnings (Accumulated Deficit) USD | Stockholders' Equity Attributable to Parent USD | Preferred Stock, Value, Issued USD | Additional Paid in Capital USD | Preferred Stock, Value, Outstanding USD | Adjustments to Additional Paid in Capital, Stock Issued, Issuance Costs USD | APIC, Share-based Payment Arrangement, Option, Increase for Cost Recognition USD |
|---|---|---|---|---|---|---|---|---|---|
| 2026-06-30 | $774.22M | $-210.00K | $-255.95M | $518.05M | (m) | (m) | (m) | (m) | (m) |
| 2026-03-31 | $764.64M | $2.00K | $-270.63M | $494.01M | (m) | (m) | (m) | (m) | (m) |
| 2025-12-31 | $750.93M | $124.00K | $-277.95M | $473.10M | (m) | (m) | (m) | (m) | (m) |
| 2025-09-30 | $738.43M | $101.00K | $-383.33M | $355.20M | (m) | (m) | (m) | (m) | (m) |
| 2025-06-30 | $725.65M | $98.00K | $-407.65M | $318.10M | (m) | (m) | (m) | (m) | (m) |
| 2025-03-31 | $709.19M | $-327.00K | $-442.56M | $266.31M | (m) | (m) | (m) | (m) | (m) |
| 2024-12-31 | $697.21M | $-364.00K | $-468.24M | $228.60M | (m) | (m) | (m) | (m) | (m) |
| 2024-09-30 | $685.25M | $-233.00K | $-475.10M | $209.92M | (m) | (m) | (m) | (m) | (m) |
| 2024-06-30 | $669.45M | $-237.00K | $-479.31M | $189.89M | (m) | (m) | (m) | (m) | (m) |
| 2024-03-31 | $651.16M | $-182.00K | $-491.51M | $159.47M | (m) | (m) | (m) | (m) | (m) |
| 2023-12-31 | $641.11M | $-199.00K | $-503.70M | $137.20M | (m) | (m) | (m) | (m) | (m) |
| 2023-09-30 | $634.46M | $-262.00K | $-507.74M | $126.46M | (m) | (m) | (m) | (m) | (m) |
| 2023-06-30 | $627.75M | $-220.00K | $-482.31M | $145.21M | (m) | (m) | (m) | (m) | (m) |
| 2023-03-31 | $674.16M | $-218.00K | $-481.31M | $192.62M | (m) | (m) | (m) | (m) | (m) |
| 2022-12-31 | $666.28M | $-225.00K | $-478.68M | $187.38M | (m) | (m) | (m) | (m) | (m) |
| 2022-09-30 | $660.06M | $-247.00K | $-471.96M | $187.86M | (m) | (m) | (m) | (m) | (m) |
| 2022-06-30 | $515.76M | $-306.00K | $-464.53M | $50.92M | (m) | (m) | (m) | (m) | (m) |
| 2022-03-31 | $513.20M | $-285.00K | $-453.01M | $59.91M | (m) | (m) | (m) | (m) | (m) |
| 2021-12-31 | $510.49M | $-188.00K | $-442.45M | $67.85M | (m) | (m) | (m) | (m) | (m) |
| 2021-09-30 | $508.46M | $-131.00K | $-429.78M | $78.55M | (m) | (m) | (m) | (m) | (m) |
| 2021-06-30 | $505.93M | $-134.00K | $-416.82M | $88.98M | (m) | (m) | (m) | (m) | (m) |
| 2021-03-31 | $503.91M | $-89.00K | $-406.15M | $97.67M | (m) | (m) | (m) | (m) | (m) |
| 2020-12-31 | $502.22M | $-95.00K | $-398.23M | $103.89M | (m) | (m) | (m) | (m) | 12 month · $2.41M |
| 2020-09-30 | $501.49M | $-16.00K | $-391.92M | $109.55M | (m) | (m) | (m) | (m) | 3 month · $700.00K |
| 2020-06-30 | $500.56M | $36.00K | $-386.83M | $113.76M | (m) | (m) | (m) | 3 month · $628.00K | 3 month · $631.00K |
| 2020-03-31 | $424.79M | $227.00K | $-378.33M | $46.68M | $0.00 | (m) | (m) | (m) | 3 month · $385.00K |
| 2019-12-28 | $424.13M | $-2.00K | $-369.48M | $54.65M | $0.00 | (m) | (m) | 12 month · $5.97M | 12 month · $854.00K |
| 2019-09-28 | (m) | $20.00K | $-360.31M | $63.47M | (m) | (m) | (m) | (m) | 3 month · $295.00K |
| 2019-06-29 | (m) | $-58.00K | $-352.03M | $71.16M | (m) | (m) | (m) | 3 month · $5.97M | 3 month · $220.00K 3 month · $220.00K |
| 2019-03-30 | $1.00K | $-67.00K | $-342.83M | $-199.04M | (m) | $143.86M | $186.52M | (m) | 3 month · $57.00K |
| 2019-03-29 | (m) | (m) | (m) | $-199.04M | (m) | (m) | (m) | (m) | 3 month · $57.00K |
| 2018-12-29 | $1.00K | $-101.00K | $-335.94M | $-192.24M | (m) | $143.79M | $186.52M | (m) | 12 month · $144.00K |
| 2018-09-29 | (m) | (m) | (m) | $-184.70M | (m) | (m) | (m) | (m) | 3 month · $31.00K |
| 2018-06-30 | (m) | (m) | (m) | $-179.66M | (m) | (m) | (m) | (m) | 3 month · $34.00K |
| 2018-03-31 | (m) | (m) | (m) | $-173.59M | (m) | (m) | (m) | (m) | 3 month · $27.00K |
| 2017-12-30 | (m) | (m) | (m) | $-168.72M | (m) | (m) | (m) | (m) | (m) |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Axogen, Inc. (AXGN) | United States | $2.329B | -73.83 |
| BIOLIFE SOLUTIONS INC (BLFS) | United States | $1.887B | 23.80 |
| LivaNova PLC (LIVN) | $4.158B | 24.01 | |
| Integer Holdings Corp (ITGR) | United States | $4.289B | 25.17 |
| CONMED Corp (CNMD) | United States | $1.353B | 26.72 |
| Ceribell, Inc. (CBLL) | United States | $0.916B | -11.27 |
| CapsoVision, Inc (CV) | United States | $0.310B | -12.68 |
| Electromed, Inc. (ELMD) | United States | $0.233B | 31.13 |
| EDAP TMS SA (FOCL) | $0.171B | ||
| Stereotaxis, Inc. (STXS) | United States | $0.130B | -7.53 |